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Abstract
Background: Toll-like receptors (TLRs), as major innate immune mediators, may be involved in clearance of cerebral
amyloid-β (Aβ) deposits. Recently, a novel TLR9 signaling pathway has been uncovered, which is functionally
associated with the immune inflammatory response and reducing Aβ burden in Alzheimer’s disease (AD) mice.
Therefore, TLR9 might represent a reasonable functional candidate gene for AD.
Findings: Our study investigated 1,133 sporadic late-onset AD (LOAD) and 1,159 healthy controls matched for sex
and age in a large Han Chinese population. One selected functional rs187084 polymorphism within the TLR9 gene
was genotyped by polymerase chain reaction-ligase detection reaction in a case–control associated study. The TLR9
rs187084 variant homozygote GG was significantly associated with a decreased LOAD risk after adjusting for age,
gender, and ApoE ε4 status by logistic regression analysis (P = 0.035). Our result showed significant evidence of the
interaction of ApoE ε4 with rs187084. When we further stratified our data by the ApoE ε4 status, we detected
significant differences in the genotype and allele distributions of rs187084 between LOAD patients and controls in
ApoE ε4 carriers (P < 0.001, P = 0.003, respectively). Moreover, we examined TLR9 expression in peripheral blood
monocytes by flow cytometry, and the GG genotype of the TLR9 rs187084 polymorphism was associated with a
higher TLR9 expression than two other genotypes in LOAD patients.
Conclusion: Our findings support the hypothesis that the TLR9 polymorphism may modify LOAD risk in the
Han Chinese population.
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Background
Alzheimer’s disease (AD) is the most common form of de-
mentia in the elderly, characterized by a slow but progres-
sive loss of cognitive function and memory [1]. The
cardinal pathological hallmark of AD is amyloid-β (Aβ) de-
posits in neuritic plaques and cerebral vessels [2] which are
closely associated with inflammatory responses such as ac-
tivated microglia in brain [3]. Increasing evidence indicates
that the immune inflammatory mechanisms are not merely
bystanders in neurodegeneration but powerful pathogenetic
forces in AD progression [4].
Toll-like receptors (TLRs) are a family of innate immune
mediators that are expressed by a variety of immune and
nonimmune cells [5]. There are at least 13 distinct TLR
family members known in mammals, of which the pathogen
specificities of 10 (TLR1-9 and 11) have been identified [6].
Like many other receptor families, TLRs act as heterodimers
to add specificity to their recognition repertoire. Among
them, TLR9 is localized to the endosomal-lysosome
compartment where it can recognize unmethylated cyto-
sine-guanosine (CpG) DNA from internalized bacteria
and viruses [7,8]. Unlike TLR2 and TLR4, TLR9 agonism
did not aggravate Aβ-induced microglial activation in
the immune response [9]. In addition, it has been demon-
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strated that activation of TLRs with their specific ligands
markedly boost uptake of Aβ, suggesting that TLR signal-
ing pathways are involved in clearance of cerebral Aβ de-
posits [10]. However, in mononuclear cells of AD patients,
transcription of TLRs upon Aβ stimulation is severely de-
pressed [11]. More importantly, recent studies have
pointed out that immune stimulation targeting TLR9
could dramatically attenuate Aβ neurotoxicity and reduce
Aβ levels in in vitro and in vivo AD models [12]. Mean-
while, this reduction in amyloid was associated with cogni-
tive improvement in AD mice [13]. Therefore,TLR9 might
represent a reasonable functional candidate gene for AD.
The human TLR9 gene is located at 3p21.3. It has
been demonstrated that polymorphisms in the TLR9
gene affect host susceptibility to a range of diseases,
such as infection, immune inflammatory diseases, and
cancers [14-17]. However, no studies have investigated
the association between TLR9 polymorphisms and sus-
ceptibility to AD. In our current study, a functional vari-
ant of rs187084 located in the promoter region of TLR9
[18] was chosen. We hypothesize that the potentially
functional rs187084 polymorphism may contribute to
AD susceptibility. To test the hypothesis, we performed
a case–control study including 1,133 LOAD cases and
1,159 healthy controls matched for sex and age in the
Han Chinese population. Then, we compare the levels of
TLR9 expression in peripheral blood monocytes of
LOAD patients among the different rs187084 genotypes.
Methods
Subjects
Our study consisted of 1,133 LOAD (age at onset ≥ 65 years)
patients and 1,159 healthy controls matched for sex and age
from the Department of Neurology of the Qingdao Munici-
pal Hospital, and several other hospitals in Shandong Prov-
ince. All of the above participants were unrelated Han
Chinese in origin. A clinical diagnosis of probable AD was
established according to the criteria of NINCDS-ADRDA
[19]. No AD patient had a family history of dementia. The
control group underwent neurological and medical examina-
tions, which showed that they were free of any symptoms
suggestive of cognitive decline. An informed consent to par-
ticipate in this study was obtained from each subject or from
a guardian, and the protocol of this study was approved by
the Ethical Committee of Qingdao Municipal Hospital.
Genotype analysis
DNA was extracted from the peripheral blood leukocytes
of patients and healthy controls using the Wizard genomic
DNA purification kit (#A1125; Promega, Madison, WI,
USA). The polymorphism at position rs187084 on chromo-
some 3p21.3 was genotyped by polymerase chain reaction-
ligase detection reaction (PCR-LDR) (TapMan Assay) on
an ABI Prism 377 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA), with technical support
from the Shanghai Genesky Biotechnology Company
[20,21]. The primer sequences used for the PCR were:
Table 1 Demographic and clinical characteristics of the study subjects
AD (n = 1,133) Control (n = 1,159) P-value
Age at examination (years) (mean ± SD) 79.94 ± 8.12 74.48 ± 6.29
Age at onset (years) (mean ± SD) 75.01 ± 8.00 0.078a
Gender, n (%)
Male 464 (41.0) 518 (44.7) 0.070
Female 669 (59.0) 641 (55.3)
MMSE (mean ± SD) 10.06 ± 3.82 28.26 ± 1.08 < 0.001
ApoE ε4 status, n (%)
ApoE ε4 carrier 315 (27.8) 158 (13.6) < 0.001
ApoE ε4 noncarrier 818 (72.2) 1,001 (86.4)
aP value was calculated with the age of onset for late-onset AD and age at examination for controls. AD, Alzheimer’s disease; ApoE ε4, apolipoprotein E ε4; MMSE,
Mini-Mental State Examination.
Table 2 rs187084 polymorphism association with Alzheimer’s disease (AD) according to different genetic models
SNP Modela Wald OR (95% CI) P P for ApoE interaction
rs187084 D 0.490 0.940 (0.791 to 1.118) 0.484 0.264
A 2.538 0.906 (0.801 to 1.023) 0.111 0.009
R 4.459 0.776 (0.613 to 0.982) 0.035 < 0.001
aThe logistic genetic models were defined as follows:
D, dominant model, defined as 1 (GG + GA) versus 0 (AA);
A, additive model, 2 (GG) versus 1 (GA) versus 0 (AA);
R, recessive model, 1 (GG) versus 0 (GA + AA).
P < 0.05 was considered significant.
ApoE, apolipoprotein E ε4; CI: confidence interval; OR: odds ratio; SNP, single-nucleotide polymorphism.
Wang et al. Journal of Neuroinflammation 2013, 10:101 Page 2 of 5
http://www.jneuroinflammation.com/content/10/1/101
forward: 5′-CGTCTTATTCCCCTGCTGGAATG-3′; re-
verse: 5′-CCTCCCAGCAGCAACAATTCAT-3′. Data ana-
lysis was achieved using GeneMapper Software v4.0 (Applied
Biosystems, Foster City, CA, USA). Results of the PCR-LDR
method corresponded with the results of sequencing for the
randomly selected DNA samples from each genotype. ApoE
was also genotyped by the PCR-LDR method.
TLR9 expression analysis by flow cytometry
Venous blood was obtained from 60 LOAD patients (20
randomly selected cases from each genotype). Whole blood
cells collected in sodium heparin tubes were stained with
fluorescein isothiocyanate (FITC)-conjugated anti-human
CD14 (BD Biosciences, San Jose, CA, USA) to identify the
monocyte population. After being washed, the cells were
permeabilized, and then stained with anti-human TLR9
antibody (eBioscience, San Diego, CA, USA). The isotype-
matched IgG2a antibody was used as control. After being
washed again, cells were incubated with phycoerythrin-
conjugated secondary antibody. Expression of TLR9 was gated
and analyzed by flow cytometry (Beckman Coulter, Fullerton,
CA, USA) as mean fluorescence intensity (MFI) with regard to
isotype control signal. The data were calculated with Cell
Quest Pro Software (Becton, Dickinson and Company, USA).
Statistical analysis
Hardy-Weinbery equilibrium (HWE) was tested with the
χ2 test to calculate genotype and allele distribution. Statis-
tical differences between AD cases and control subjects
were also tested when we stratified our data by ApoE ε4
status. Differences in the characteristics for our subjects
were examined using the Student t-test or the χ2 test.
Odds ratio (OR) and 95% confidence intervals (CIs) were
tested using logistic regression models after adjustment for
sex, age, and ApoE ε4 status under various genetic models
that were defined as 1 (GG +GA) versus 0 (AA) for do-
minant, 2 (GG) versus 1 (GA) versus 0 (AA) for additive,
and 1 (GG) versus 0 (GA +AA) for recessive. All statistical
analyses were performed by IBM SSPS statistics 19.0 (IBM
Company, USA). The statistical power of the study was
calculated by STPLAN43 software. The level of signifi-
cance for all statistical tests was defined as P < 0.05.
Results
The distribution of the TLR9 (rs187084) was in HWE
for both AD patients and controls (P > 0.05). Allele and
genotype frequencies of rs187084 in our control group
were consistent with the CHB (Han Chinese in Beijing)
genotype data in the HapMap database. Demographic
and clinical characteristics of the participants are shown
in Table 1. There were no differences for gender (P =
0.070) and age (P = 0.078) between AD and controls. We
found significantly lower Mini-Mental State Examination
(MMSE) scores in LOAD patients compared to the
Table 3 Genotype and allele frequencies for rs187084 stratified by apolipoprotein E ε4 (ApoE) status
rs187084 n Genotype P Allele P OR (95% CI)
GG (%) GA (%) AA (%) G (%) A (%)
AD 1,133 150 (13.2) 557 (49.2) 426 (37.6) 0.100 857 (37.8) 1,409 (62.6) 0.076 0.898 (0.798 to 1.011)
Control 1,159 190 (16.4) 556 (48.0) 413 (35.6) 936 (40.4) 1,382 (59.6)
ApoE ε4 carriers
AD 315 30 (9.5) 156 (49.5) 129 (40.1) < 0.001 216 (34.3) 414 (65.7) 0.003 0.656 (0.498 to 0.865)
Control 158 38 (24.1) 64 (40.5) 56 (35.4) 140 (44.3) 176 (55.7)
ApoE ε4 noncarriers
AD 818 120 (14.7) 401(49.0) 297 (36.3) 0.936 641 (39.2) 995 (60.8) 0.722 0.976 (0.854 to 1.116)
Control 1,001 152 (15.2) 492 (49.2) 357 (35.7) 796 (39.8) 1,206 (60.2)
AD, Alzheimer’s disease; ApoE ε4, apolipoprotein E ε4; CI, confidence interval; OR, odds ratio.
Figure 1 Toll-like receptor 9 (TLR9) expression in peripheral
blood monocytes of late-onset Alzheimer’s disease (LOAD)
patients according to TLR9 genotypes. Results are expressed as
mean fluorescent intensity (MFI) units by flow cytometry. Statistically
significant differences between TLR9 genotypes are indicated.
Wang et al. Journal of Neuroinflammation 2013, 10:101 Page 3 of 5
http://www.jneuroinflammation.com/content/10/1/101
controls (P < 0.001). As expected, the ApoE ε4 allele
frequency was also significantly different between AD
patients and controls (P < 0.001).
We evaluated single-nucleotide polymorphism (SNP)
rs187084 effects under different models using logistic
regression adjusting for age, gender, and ApoE ε4 status.
The rs187084 was found to significantly decrease the risk
of developing LOAD in a recessive model (OR = 0.776,
95% CI = 0.613 to 0.982), but not in dominant or additive
models. Besides, an interaction between rs187084 poly-
morphism and ApoE was also observed in different ge-
netic models (Table 2). When we further stratified our
data according to ApoE ε4 status, we detected significant
differences in the genotype and allele distributions of
rs187084 between LOAD patients and controls in ApoE
ε4 carriers (P < 0.001, P = 0.003, respectively); and the
rs187084 minor G-allele significantly decreased the risk of
LOAD (OR = 0.656, 95% CI: 0.498 to 0.865). However, no
significant frequency differences between AD and controls
at allelic and genotype levels were observed in the total
sample or in ApoE ε4 noncarriers (Table 3).
We further compared TLR9 levels in peripheral blood
monocytes of LOAD patients among the different
rs187084 genotypes. Our results showed that the GG
genotype of the TLR9 rs187084 polymorphism was associ-
ated with a higher TLR9 expression than two other geno-
types in LOAD patients (Figure 1).
Discussion
To the best of our knowledge, this is the first study to
evaluate whether the TLR9 rs187084 polymorphism
could influence susceptibility to LOAD in a large Han
Chinese population. Logistic regression analyses showed
that the rs187084 variant homozygote GG was associ-
ated with a significantly decreased LOAD risk (OR =
0.776, 95% CI = 0.613 to 0.982) in the recessive genetic
model. Moreover, rs187084 showed a significant ApoE
interaction. After stratifying our data by ApoE ε4 status,
we detected significant differences in the genotype and
allele distributions of rs187084 between LOAD patients
and controls in ApoE ε4 carriers. The minor G allele
was revealed to be associated with a decreased risk of
LOAD. These findings indicate that the G allele of
rs187084 is the protective allele against the development
of LOAD. More importantly, the GG genotype of TLR9
rs187084 polymorphism was associated with a higher
TLR9 expression than two other genotypes in LOAD
patients.
The TLR9 rs187084 is a potentially functional variant lo-
cated in the promoter region [18] which may regulate the
TLR9 transcript levels and protein function. Several stud-
ies have investigated the effect of rs187084 polymorphism
on human diseases, such as rheumatoid arthritis [14], sys-
temic lupus erythematosus [22], symptomatic malaria
[23], Graves’ ophthalmopathy [24], and cervical cancer
[17]. In the current study, we found that the rs187084
variant within TLR9 affected susceptibility to LOAD in a
large Han Chinese population. The minor G allele signifi-
cantly decreased the risk of LOAD, and GG genotype up-
regulated TLR9 expression in peripheral blood monocytes
of LOAD patients, demonstrating that functionality of the
rs187084 polymorphism could change TLR9 expression.
Considering the key role of TLR9 in clearance of cerebral
Aβ in AD progression [13], this functional variant might
play a protective role in AD by increasing Aβ clearance.
In-depth studies are greatly needed to confirm the func-
tionality of the rs187084 polymorphism in the brain, and
elucidate its detailed role in AD pathogenesis. In addition,
only one selected SNP within the TLR9 gene was geno-
typed in our study. Future comprehensive investigation of
the association between other polymorphisms in TLR9
and AD susceptibility is also warranted.
Conclusion
Our study demonstrated an association between TLR9
rs187084 polymorphism and LOAD risk. The G allele
was revealed to be a protective factor for the LOAD in a
Han Chinese population. However, it remains unknown
whether it is applicable to other ethnic groups. Different
populations and larger sample studies are necessary to
validate our findings and further clarify the possible role
of TLR9 in LOAD.
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